Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep;53(9):3989-91.
doi: 10.1128/AAC.00722-09. Epub 2009 Jul 13.

The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently

Robert Gelber  1 , Koen Andries, Rose Maria D Paredes, Cora Evelyn S Andaya, Jasmin Burgos
Affiliations

The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently

Robert Gelber et al. Antimicrob Agents Chemother. 2009 Sep.

Abstract

The diarylquinoline R207910 is profoundly bactericidal in a murine model of tuberculosis. Previously, R207910 was also found to be bactericidal for Mycobacterium leprae-infected mice during lag phase. Herein we evaluate the bactericidal efficacy of R207910 (1 to 120 mg/kg of body weight) when administered five times weekly, once weekly, and once monthly during logarithmic multiplication of M. leprae organisms. All treatments were found to be bactericidal, suggesting that both low and intermittent dosing with R207910 holds promise for leprosy patients.

PubMed Disclaimer

References

    1. Andries, K., P. Verhasselt, J. Guillemont, H. W. H. Göhlmann, J.-M. Neefs, H. Winkler, J. Van Gestel, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. de Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis, and V. Jarlier. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. - PubMed
    1. Blumberg, H. M., W. J. Burman, R. E. Chaisson, C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. R. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reves, L. B. Reichman, P. M. Simone, J. R. Starke, and A. A. Vernon. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662. - PubMed
    1. Chan, G. P., B. Y. Garcia-Ignacio, V. E. Chavez, J. B. Livelo, C. L. Jimenez, M. L. R. Parilla, and S. G. Franzblau. 1994. Clinical trial of clarithromycin for lepromatous leprosy. Antimicrob. Agents Chemother. 38:515-517. - PMC - PubMed
    1. Fajardo, T. T., L. G. Villahermosa, E. C. dela Cruz, R. M. Abalos, S. G. Franzblau, and G. P. Walsh. 1995. Minocycline in lepromatous leprosy. Int. J. Lepr. 63:8-17. - PubMed
    1. Fajardo, T. T., L. G. Villahermosa, E. C. dela Cruz, R. V. Cellona, M. V. Balagon, R. M. Abalos, and R. H. Gelber. 2004. A clinical trial of pefloxacin and ofloxacin in lepromatous leprosy. Lepr. Rev. 75:389-397. - PubMed

Publication types

MeSH terms

LinkOut - more resources